Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:444795
Structure:
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7
15-Apo-beta-caroten-15-oic acid
1n4h
2,4, 6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2E, 4E, 6E, 8E)-
2,4,6,8-Nonatetraenoic acid,
2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-
2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-
2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)
3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid
302-79-4
4-09-00-02387 (Beilstein Handbook Reference)
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-CIS-RETINOIC ACID
9-cis-Tretinoin
A-Acido (Argentina)
A-Vitaminsyre [Denmark]
Aberel
Aberela [Norway]
Acid A Vit (Belgium, Netherlands)
Acide retinoique (French) (DSL)
Acnavit [Denmark]
AGN 100335
AGN 192013
AIDS-000179
AIDS000179
Airol
Aknefug
Aknoten
Alitretinoin
Alitretinoin (USAN)
Alitretinoin [USAN]
all trans retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
All-trans Retinoic Acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
all-trans-Retinoate
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
Alltrans-retinoic acid
ALRT 1057
ALRT-1057
ATRA
Atragen
Atralin
Avita
Avita (TN)
Avita Gel
Avitoin [Norway]
b-Retinoic acid
BAL4079
beta-RA
beta-Retinoic acid
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
C00777
C20H28O2
CCRIS 3294
CCRIS 7098
CHEBI:15367
Cordes vas
Cordes VAS [Germany]
D00094
D02815
DB00523
Dermairol
DRG-0147
DRG-0281
Effederm
Effederm [France]
EINECS 206-129-0
Epi-aberel
EU-0101061
Eudyna
HSDB 2169
HSDB 7186
IDI1_000903
IDI1_033970
LGD 100057
LGD 1057
LMPR01090019
Lopac0_001061
LS-1154
Mixture Name
MLS000028588
MLS001076515
NCGC00021808-04
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
nchembio.154-comp2
NSC 122758
NSC 659772
NSC-122758
NSC122758
Panretin
Panretin (TN)
Panretin Gel
Panretyn
Panrexin
PDT-002-002
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R2625_SIGMA
RA
REA
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
RETIN-A MICRO
Retinoate
Retinoic acid
Retinoic acid, 9-cis-
Retinoic acid, all-trans-
Retinoic acid, all-trans- (8CI)
Retinoic acid, cis-9,trans-13-
Retinova
Retionic acid
Retisol-A
Ro 1-5488
SMR000058245
SOLAGE
SPECTRUM1502016
Spectrum5_001746
Spectrum5_001933
ST057075
Stieva-A
trans-Retinoic acid
Tretin M
TRETINOIN
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
tretinoin liposome
Tretinoin [USAN:BAN:INN]
Tretinoin [USAN:INN:BAN]
Tretinoin, all-trans-
Tretinoina [INN-Spanish]
Tretinoine (French) (EINECS)
Tretinoine [INN-French]
Tretinoino [INN-Spanish]
Tretinoinum [INN-Latin]
TRETINON
TRI-LUMA
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesnaroid
Vitamin A acid
Vitamin A acid, all-trans-
Vitamin a acid, trans-
Vitamin A1 acid, all-trans-
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
ATC-Codes:

Target

show target details
Uniprot ID:Q9Y354_HUMAN
Synonyms:
Matrix metalloproteinase 9
EC-Numbers:3.4.24.35
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

18571505
Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells.. Gudrun Reiterer; Rodica P Bunaciu; James L Smith; Andrew Yen (2008) FEBS letters display abstract
PDGFR inhibitors are successfully used in a number of cancer treatments. The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA). However, the relapse rates are significant. In the present work we evaluated the effects of RA therapy in the presence of PDGFR inhibitor, AG1296. Adding AG1296 with RA increased secretion of TNF-alpha, IL-8, and MMP-9 expression. This treatment induced higher levels of ICAM-1 endothelial cell expression, and increased cellular mobility. Inhibiting PDGFR enhanced RA-induced expression of integrin. Integrin ligand increased differentiation markers CD11b, inducible oxidative metabolism and PDGFR-beta phosphorylation. While the neutrophil-endothelial cell interactions are strengthened by the combined treatment, the endothelium-substratum interactions are weakened, a situation common in RAS.